Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer
The primary objective is to evaluate in participants with high-grade serous ovarian cancer (HGSOC), whether the reduction from baseline in circulating tumor DNA (ctDNA) at Cycle 3 (ΔctDNA) is larger in